Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
2016 · New England Journal of Medicine · 1,957 citations
https://doi.org/10.1056/nejmoa1609709
C
Carlos L. Arteaga
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.3K
Papers
55.3K
Citations
123
h-index
388
i10-index
Carlos L. Arteaga is an academic researcher from Southwestern Medical Center. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 123, co-authored 1114 publications.
ORCID: 0000-0003-0870-9586Papers by this author
worksERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
2014 · Cancer Cell · 1,054 citations
https://doi.org/10.1016/j.ccr.2014.02.025
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
2018 · Annals of Oncology · 839 citations
https://doi.org/10.1093/annonc/mdy155
The PI3K/AKT Pathway as a Target for Cancer Treatment
2015 · Annual Review of Medicine · 826 citations
https://doi.org/10.1146/annurev-med-062913-051343
HER kinase inhibition in patients with HER2- and HER3-mutant cancers
2018 · Nature · 769 citations
https://doi.org/10.1038/nature25475
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
2002 · PubMed · 617 citations
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat